Abstract:
PURPOSE: An external use skin composition containing Caesapinia sappan L. extract and cell permeable HSP27 fusion protein is provided to suppress edema and to ensure anti-inflammation. CONSTITUTION: An external use composition for anti-inflammation contains each 0.001-50 wt% of Caesapinia sappan L. extract, Siegesbeckia glabrescens Makino extract, and cell permeable HSP27 fusion protein. The cell permeable HSP27 fusion protein is Pep-HSP27 fusion protein. The external use skin composition is manufactured in the form of a lotion, gel, water soluble liquid, cream, essence, and water-in-oil type or oil-in-water formulation. The composition is a pharmaceutical or cosmetic composition.
Abstract:
PURPOSE: An external use composition containing Siegesbeckia glabrescens Makino extract and cell permeable HSP27 fusion protein is provided to effectively treat atopic dermatitis and acne. CONSTITUTION: An external use composition for anti-inflammation contains 0.001-50 wt% of Siegesbeckia glabrescens Makino extract and cell permeable HSP27 fusion protein. The composition is a pharmaceutical composition or cosmetic composition. The composition is manufactured in the form of a tonic, lotion, emulsion, cream, ointment, gel, spray, mousse, capsule, or plaster. The daily dose of the composition is 0.0001-100 mg/kg.
Abstract:
본 발명은 알츠하이머질병(Alzheimer's Disease)의 예방, 치료 및 인지능 개선을 목적으로, 상기 추출물은 아세틸콜린에스테라제의 활성을 저해함으로써 아세틸콜린의 농도를 증가시켜, 콜린성 신경기능 퇴화로 인한 알츠하이머병의 예방 및 치료에 효과적이다. 또한 베타아밀로이드 펩타이드의 생성과정에 관여하는 효소의 하나인 β-세크레타제(β-site Amyloid precursor protein Cleaving Enzyme, BACE)의 활성을 특이적으로 저해하는 구멍쇠미역 추출물을 포함하는 것을 특징으로 하는 치매 예방 또는 치료 및 인지능 개선용 약학적 조성물 또는 기능성 식품 조성물에 관한 것이다. 치매, 예방, 치료, 아세틸콜린에스테라아제, 베타세크레타제
Abstract:
본 발명은 까실쑥부쟁이 추출물을 유효성분으로 포함하는 당뇨합병증 치료 또는 예방용 조성물에 관한 것이다. 상기 까실쑥부쟁이 추출물은 항산화 활성과 알도스 환원효소 억제활성 및 최종당화산물 억제작용이 우수한 것으로 확인되었을 뿐만 아니라, 천연물 추출물이므로 부작용과 안전성 관련 문제가 거의 없으므로, 이를 유효성분으로 포함하는 상기 약학 조성물 또는 건강 기능성 식품 조성물은 당뇨합병증의 치료, 예방 또는 개선을 위하여 사용될 수 있다.
Abstract:
PURPOSE: A composition containing isoangustone A is provided to reduce collagen generation and to reduce tissue inhibitor of metalloproteinase type 2(TIMP-2) activity. CONSTITUTION: A composition for suppressing renalfibrosis or glomerulsclerosis contains isoangustone A which is an ingredient of Glycyrrhiza uralensis extract. Isoangustone A has a structure of chemical formula I. A method for isolating isoangustone A comprises: a step of extracting Glycyrrhiza uralensis roots using a solvent of hexane and ethanol by sonication for one hour; a step of decompression-concentrating the extract to prepare crude extract; and a step of performing HSCCC(High-speed countercurrent chromatography).
Abstract:
PURPOSE: A pharmaceutical or functional food composition containing Agarum clathratum extract is provided to enhance acetylcholine concentration and to prevent and treat Alzheimer's disease. CONSTITUTION: A pharmaceutical composition or functional food composition for preventing or treating dementia contains 0.1-99 weight% of Agarum clathratum extract. The Agarum clathratum extract is isolated using water or 50-100% low alcohol of C1-C4. A pharmaceutical composition or functional food composition for improving cognition contains 0.01-15 weight% of the composition .The pharmaceutical composition further contains pharmaceutically acceptable carrier, diluent, or excipient.
Abstract:
본 발명은 흰색 감국 추출물을 유효성분으로 포함하는 허혈성 뇌혈관 질환 예방 또는 개선용 조성물에 관한 것으로, 보다 상세하게는 뇌허혈에 민감하다고 알려져 있는 뇌 해마조직 CA1 영역의 신경 손상을 효과적으로 예방할 뿐만 아니라, 인체에 무해한 흰색 감국 추출물을 유효성분으로 포함하는 허혈성 뇌혈관 질환 예방 또는 개선용 조성물에 관한 것이다. 흰색 감국, 허혈성 뇌혈관 질환, 치매, 알츠하이머
Abstract:
PURPOSE: A composition containing licochalcone A is provided to prevent and treat sepsis without toxic effects. CONSTITUTION: A pharmaceutical composition for preventing and treating sepsis contains licochalcone A or a pharmaceutically acceptable salt thereof as an active ingredient. Licochalcone A is a major flavonoid isolated from Glycyrrhizae radix. The content of licochalcone A is 0.01-99.9 weight%. The pharmaceutical composition is used in the form of a powder, granule, tablet, capsule, suspension, emulsion, syrup, aerosol, external use formulation, suppository, or injection.
Abstract:
A composition for preventing or treating brain ischemia diseases, which contains white Chrysanthemum indicum Var. albescens as an active ingredient is provided to prevent nerve injury of CA1 area of brain hippocampus. A composition for preventing and treating brain ischemia diseases comprises 0.001-99.99 weight% of Chrysanthemum indicum var. albescens extract as an active ingredient. The brain ischemia diseases are cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage and white matter. The Chrysanthemum indicum var. albescens extract is isolated with 30-80% of alcohol solution of 1-5 carbon atoms. The composition further comprises a carrier, excipient, and diluents. The composition is used in a form of powder, granule, tablet, suspension, emulsion or syrup.
Abstract:
A manufacturing method of anti-obesity composition is provided to have excellent obesity inhibition effect using ligustilide separated from the Cnidii Rhizoma fractions. A manufacturing method of anti-obesity composition comprises steps of: preparing cnidii Rhizoma; dipping prepared Cnidii Rhizoma in ethanol, extracting it and manufacturing Cnidii Rhizoma extract; manufacturing the Cnidii Rhizoma extraction concentrate by concentrating the Cnidii Rhizoma extract; putting water into the manufactured Cnidii Rhizoma extraction concentrate, partitioning it into hexane, concentrating it and manufacturing the Cnidii Rhizoma fractions; and obtaining active compound containing ligustilide component by gushing out the manufactured Cnidii Rhizoma fractions to silica gel column.